Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics.
Meyer M, Mahr A, Brewer J, Daniel V, Dell'Aringa J, Goldstone T, Hersey S, Johnston I, Larson P, Loveridge M, MacBeath G, Moyer M, Nagorsen D, Papa S, Peiser L, Ranade K, Rizzi R, Roers A, Schendel D, Sivakumar P, Tran E, Türeci Ö, Weigand L, Wennborg A, Williams D, Yee C, Britten CM. Meyer M, et al. Among authors: nagorsen d. Nat Rev Drug Discov. 2024 Jan;23(1):1-2. doi: 10.1038/d41573-023-00189-4. Nat Rev Drug Discov. 2024. PMID: 38030734 No abstract available.
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. Among authors: nagorsen d. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. J Clin Oncol. 2023. PMID: 36689692 Free PMC article. Clinical Trial.
Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.
Khaldoyanidi S, Nagorsen D, Stein A, Ossenkoppele G, Subklewe M. Khaldoyanidi S, et al. Among authors: nagorsen d. J Clin Oncol. 2021 Feb 10;39(5):419-432. doi: 10.1200/JCO.20.00475. Epub 2021 Jan 12. J Clin Oncol. 2021. PMID: 33434043 Free PMC article. Review. No abstract available.
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Razak AR, Cleary JM, Moreno V, Boyer M, Calvo Aller E, Edenfield W, Tie J, Harvey RD, Rutten A, Shah MA, Olszanski AJ, Jäger D, Lakhani N, Ryan DP, Rasmussen E, Juan G, Wong H, Soman N, Smit MD, Nagorsen D, Papadopoulos KP. Razak AR, et al. Among authors: nagorsen d. J Immunother Cancer. 2020 Oct;8(2):e001006. doi: 10.1136/jitc-2020-001006. J Immunother Cancer. 2020. PMID: 33046621 Free PMC article.
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Gökbuget N, Kantarjian HM, Brüggemann M, Stein AS, Bargou RC, Dombret H, Fielding AK, Heffner L, Rigal-Huguet F, Litzow M, O'Brien S, Zugmaier G, Gao S, Nagorsen D, Forman SJ, Topp MS. Gökbuget N, et al. Among authors: nagorsen d. Blood Adv. 2019 Oct 22;3(20):3033-3037. doi: 10.1182/bloodadvances.2019000457. Blood Adv. 2019. PMID: 31648325 Free PMC article.
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W. Stamm H, et al. Among authors: nagorsen d. Oncogene. 2018 Sep;37(39):5269-5280. doi: 10.1038/s41388-018-0288-y. Epub 2018 May 31. Oncogene. 2018. PMID: 29855615 Free PMC article.
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Gökbuget N, et al. Among authors: nagorsen d. Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Blood. 2018. PMID: 29358182 Free PMC article. Clinical Trial.
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore BM, Nagorsen D, Hill JS, Stephenson J Jr. Papadopoulos KP, et al. Among authors: nagorsen d. Clin Cancer Res. 2017 Oct 1;23(19):5703-5710. doi: 10.1158/1078-0432.CCR-16-3261. Epub 2017 Jun 27. Clin Cancer Res. 2017. PMID: 28655795 Clinical Trial.
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Kantarjian H, et al. Among authors: nagorsen d. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783. N Engl J Med. 2017. PMID: 28249141 Free PMC article. Clinical Trial.
72 results